Disease

• Disease
• Anatomy & Physiology
• Valve Disease
• Ischemic Heart Disease
• Ventricular Remodeling
• Congestive Heart Failure

Treatment

• Treatment
• Replace or Repair
• IMVR
• Revascularization
  and Repair

Technology

• Dynaplasty Technology

News/Events

• News/Events
• Press Releases
• Event Calendar

MiCardia Corporation is an early-stage venture dedicated to designing, developing and commercializing minimally invasive methods of mitral and tricuspid valve treatment. Formed in November 2004, MiCardia has been dedicated to developing treatments for Mitral Regurgitation (MR) Recurrence, Tricuspid Regurgitation Recurrence, Mitral Valve Prolapse, Ischemic Heart Disease and Congestive Heart Failure (CHF).

Since its inception, the company has built an experienced technical and clinical team, while creating a comprehensive intellectual property portfolio. Proof of concept has been completed for a Dynamically Activated Annuloplasty Ring with novel methods for off-pump intra-operative and chronic percutaneous activation methods.